News | Novartis novartis.com

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

novartis.com·1w

Novartis partners with Special Olympics World Winter Games Switzerland 2029

novartis.com·1w

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

novartis.com·2w

Full Circle: A Story of Growth, Purpose and Coming Home to Novartis

novartis.com·2w

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

novartis.com·2w

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

novartis.com·2w

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

novartis.com·2w

Novartis withdraws EMA application for adding new indication for Pluvicto®

novartis.com·3w

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

novartis.com·3w

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

novartis.com·3w

New long term social impact and sustainability targets

novartis.com·4w

Working with communities to close gaps in heart disease and cancer care

novartis.com·5w

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

novartis.com·5w

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

novartis.com·7w

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

novartis.com·7w

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

novartis.com·7w

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

novartis.com·8w

AI, Game Studio, XR & Emerging Tech

novartis.com·8w

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

novartis.com·9w

Bringing proteins together to take cancer apart

novartis.com·9w

Log in to enable infinite scrolling